Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average rating of “Moderate Buy” from the twenty-two research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, twenty have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $118.0952.

A number of equities research analysts have recently commented on the company. UBS Group increased their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Citigroup increased their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Finally, Barclays increased their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th.

Insider Buying and Selling

In other news, COO Jeremy G. Chadwick sold 300 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total value of $27,000.00. Following the completion of the sale, the chief operating officer owned 61,202 shares in the company, valued at $5,508,180. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce Booth sold 5,900 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director owned 5,641 shares of the company’s stock, valued at $507,464.36. The trade was a 51.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 383,734 shares of company stock valued at $32,454,902. 15.98% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently modified their holdings of KYMR. Smartleaf Asset Management LLC lifted its holdings in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after acquiring an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth $63,000.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $78.14 on Wednesday. Kymera Therapeutics has a one year low of $28.06 and a one year high of $103.00. The stock has a fifty day moving average of $83.40 and a 200-day moving average of $78.31. The company has a market capitalization of $6.43 billion, a PE ratio of -21.89 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the prior year, the firm earned ($0.82) EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, research analysts forecast that Kymera Therapeutics will post -3.34 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.